DOCSLIB.ORG

Response to Growth Hormone in Attention Deficit Hyperactivity Disorder: Effects of Methylphenidate and Pemoline Therapy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Response to Growth Hormone in Attention Deficit Hyperactivity Disorder: Effects of Methylphenidate and Pemoline Therapy Response to Growth Hormone in Attention Deficit Hyperactivity Disorder: Effects of Methylphenidate and Pemoline Therapy Jayashree K. Rao, MD*; Joanne R. Julius, MS‡; Timothy J. Breen, PhD‡; and Sandra L. Blethen, MD, PhD‡ ABSTRACT. Objective. To determine whether treat- he treatment of attention deficit hyperactiv- ment of attention deficit hyperactivity disorder (ADHD) ity disorder (ADHD) with methylphenidate with methylphenidate hydrochloride or pemoline dimin- hydrochloride or pemoline is associated with ishes the response to growth hormone (GH) therapy in T short-term growth deceleration. Decreased appe- patients with idiopathic GH deficiency (IGHD) or tite that leads to low weight gain has been pro- idiopathic short stature (ISS). posed as the cause of this slow growth, and most Methods. The National Cooperative Growth Study children will have catch-up growth after treatment database was used to identify patients between 3 and 20 1–4 years of age with IGHD or ISS and those within these with these agents has been discontinued. There groups who were treated with methylphenidate or pemo- is evidence that alterations in dopaminergic path- 1,5 line for ADHD. Their growth in response to GH treat- ways have a role in the pathogenesis of ADHD. ment (change in height standard deviation score [SDS]) Because dopaminergic pathways also are involved was compared with that of patients with IGHD or ISS in the regulation of growth hormone (GH) secre- who were not treated for ADHD, by using a stepwise tion,6 the association between growth failure and multiple regression analysis. ADHD also may have an endocrine cause. It is also Results. In the IGHD cohort, there were 184 pa- possible that medications such as methylphenidate tients who were being treated for ADHD and 2313 who and pemoline have direct effects on cartilage me- were not. In the ISS cohort there were 117 patients who tabolism.7 were being treated for ADHD and 1283 who were not. We studied the effects of therapy with methyl- There was a higher percentage of males being treated phenidate or pemoline on growth in response to for ADHD in both cohorts. In the IGHD cohort, the change in height SDS was positively associated with exogenous GH in patients with both ADHD and the number of years of GH treatment, parents’ heights, idiopathic growth hormone deficiency (IGHD) or id- body mass index, and GH injection schedule, and was iopathic short stature (ISS), using a large North negatively associated with height SDS at the initiation American database of patients treated with GH, the of GH therapy, age, and maximum stimulated GH National Cooperative Growth Study (NCGS). level. The use of methylphenidate or pemoline had a negative effect on the change in height SDS, but the PATIENTS AND METHODS magnitude of the effect was small. Similar effects were noted in the ISS cohort, but body mass index and the Patients use of methylphenidate or pemoline had no effect on The NCGS is a postmarketing database of patients in the United the change in height SDS. States and Canada who have been treated with GH products Conclusions. Concurrent ADHD therapy is associated manufactured by Genentech Inc (South San Francisco, CA). The methods of patient enrollment and data collection have been with a slight decrease in the change in height SDS during described previously.8 Patients in the NCGS database were in- GH treatment in patients with IGHD but not in those cluded in this analysis if they met the following criteria: 1) diag- with ISS. Even in IGHD, the magnitude of the effect is nosis of IGHD or ISS as determined by the treating physician small and should not deter the use of such concurrent (confirmed by a maximum stimulated GH level ,10 mg/L for therapy. Pediatrics 1998;102:497–500; attention deficit hy- IGHD and $10 mg/L for ISS); 2) no GH therapy before enrollment; peractivity disorder, methylphenidate, pemoline, growth 3) prepubertal at enrollment; 4) between 3 and 20 years of age at hormone, idiopathic growth hormone deficiency, idio- enrollment; 5) height below the 5th percentile for age and sex; 6) pathic short stature. no other significant medical conditions that affect growth; and 7) height reported after at least 180 days of GH therapy. Patients who met the criteria above and who also were treated for ADHD with ABBREVIATIONS. ADHD, attention deficit hyperactivity disor- either methylphenidate or pemoline were identified. The informa- der; GH, growth hormone; IGHD, idiopathic growth hormone tion provided on the case report forms was used for the analysis. The GH levels were determined at laboratories chosen by the deficiency; ISS, idiopathic short stature; NCGS, National Cooper- treating physician. ative Growth Study; SDS, standard deviation score(s); BMI, body mass index. Statistics Descriptive data are reported as mean 6 SD for continuous variables and as percentages for categorical variables. Height SD From the *Department of Pediatrics, Louisiana State University School of scores (SDS) were calculated as follows: SDS 5 (height 2 mean Medicine, New Orleans, Louisiana; and the ‡Department of Medical Af- height of normal persons of the same age and sex)/(SD of height fairs, Genentech Inc, South San Francisco, California. of normal persons of the same age and sex). Height and weight This work was presented in part at the National Cooperative Growth Study standards were obtained from data collected by the National Eleventh Annual Investigators Meeting, September 25–28, 1997, Washing- Center for Health Statistics.9 Differences in the mean values be- ton, DC. tween the ADHD and comparison groups were tested by using Received for publication Feb 6, 1998; accepted Mar 20, 1998. Student’s t tests and differences in the proportions were tested by Address correspondence to Jayashree K. Rao, MD, Department of Pediat- using x2 tests. rics, Louisiana State University School of Medicine, 1542 Tulane Ave, New The response to GH therapy was defined as the change in Orleans, LA 70112. height SDS from the time that GH therapy was initiated to the PEDIATRICS (ISSN 0031 4005). Copyright © 1998 by the American Acad- time of the most recent height measurement or the height emy of Pediatrics. measurement when treatment was discontinued, whichever oc- Downloaded from www.aappublications.org/news by guest on October 2, 2021 SUPPLEMENT 497 TABLE 1. Patient Characteristics ADHD–IGHD IGHD ADHD–ISS ISS (n 5 184) (n 5 2313) (n 5 117) (n 5 1283) Male sex, number (%) 161 (88)** 1699 (73) 99 (85)* 957 (75) Entered puberty during treatment, number (%) 87 (47) 1095 (47) 54 (46) 657 (51) GH injected $4 times a week, number (%) 157 (85) 1791 (77) 94 (80) 1006 (78) Age at enrollment, y 9.2 6 3.0 9.1 6 3.5 9.2 6 2.8 9.6 6 3.1 Height SDS 22.8 6 0.7** 23.0 6 0.9 22.8 6 0.7 22.9 6 0.7 Maximum stimulated GH level, mg/L 5.9 6 2.4** 5.6 6 2.7 16.1 6 5.8 17.7 6 9.5 BMI (kg/m2) 15.7 6 2.1*** 16.5 6 2.9 15.4 6 1.6** 15.9 6 2.0 Bone age deficit, y 2.0 6 1.0* 2.2 6 1.3 2.0 6 1.1 2.2 6 1.3 Maternal height SDS 20.7 6 1.2 20.8 6 1.3 21.0 6 1.7 21.1 6 1.2 Paternal height SDS 20.3 6 1.2 20.5 6 1.2 20.5 6 1.3* 20.7 6 1.3 Years of GH therapy 3.0 6 2.0 2.7 6 1.8 2.8 6 1.9 2.7 6 1.8 Change in height SDS 1.2 6 0.8** 1.3 6 0.9 1.0 6 0.7 1.1 6 0.7 * P , .05; ** P , .01; *** P , .001. Comparisons are between ADHD–IGHD and IGHD or between ADHD–ISS and ISS, as appropriate. curred first. This definition of response (as opposed to yearly Enrollment Characteristics growth rates) avoids problems associated with annualizing growth data for intervals different from 12 months and makes Enrollment characteristics of the groups are shown it possible to use data from all patients (including dropouts) in in Table 1. the analysis, thereby eliminating concerns about possible patient-selection bias. Multiple stepwise regression analysis IGHD Cohort was used for determining the relative influence of the following There were small but significant differences be- variables on the change in height SDS: age at enrollment, sex, height SDS at enrollment, body mass index (BMI), mother’s tween the ADHD–IGHD group and the IGHD group height SDS, father’s height SDS, maximum stimulated GH level, in several variables that have been shown to predict frequency of GH injections, onset of puberty during therapy, the response to GH therapy. These were height SDS and methylphenidate or pemoline therapy. at enrollment (22.8 6 0.7 vs 23.0 6 0.9; P , .01), A result was considered statistically significant if the P value 6 6 was , .05. All statistical analyses were performed by using the maximum stimulated GH level (5.9 2.4 vs 5.6 2.7 2 Statistical Analysis System (SAS version 6.11, SAS Institute Inc, mg/L; P , .01); BMI (15.7 6 2.1 vs 16.5 6 2.9 kg/m ; Cary, NC). P , .001), and GH injection schedule (cumulative weighted average $4 times a week, 85% vs 77%; P , RESULTS .05). Other predictive variables, including age at en- We identified a total of 3897 patients who met the rollment, parental heights, and weekly GH dose, that entry criteria, 301 of whom also had been treated have been shown previously to be important were with methylphenidate or pemoline for ADHD.
Load more

Recommended publications
  • Methylphenidate Hydrochloride
    Application for Inclusion to the 22nd Expert Committee on the Selection and Use of Essential Medicines: METHYLPHENIDATE HYDROCHLORIDE December 7, 2018 Submitted by: Patricia Moscibrodzki, M.P.H., and Craig L. Katz, M.D. The Icahn School of Medicine at Mount Sinai Graduate Program in Public Health New York NY, United States Contact: [email protected] TABLE OF CONTENTS Page 3 Summary Statement Page 4 Focal Point Person in WHO Page 5 Name of Organizations Consulted Page 6 International Nonproprietary Name Page 7 Formulations Proposed for Inclusion Page 8 International Availability Page 10 Listing Requested Page 11 Public Health Relevance Page 13 Treatment Details Page 19 Comparative Effectiveness Page 29 Comparative Safety Page 41 Comparative Cost and Cost-Effectiveness Page 45 Regulatory Status Page 48 Pharmacoepial Standards Page 49 Text for the WHO Model Formulary Page 52 References Page 61 Appendix – Letters of Support 2 1. Summary Statement of the Proposal for Inclusion of Methylphenidate Methylphenidate (MPH), a central nervous system (CNS) stimulant, of the phenethylamine class, is proposed for inclusion in the WHO Model List of Essential Medications (EML) & the Model List of Essential Medications for Children (EMLc) for treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) under ICD-11, 6C9Z mental, behavioral or neurodevelopmental disorder, disruptive behavior or dissocial disorders. To date, the list of essential medications does not include stimulants, which play a critical role in the treatment of psychotic disorders. Methylphenidate is proposed for inclusion on the complimentary list for both children and adults. This application provides a systematic review of the use, efficacy, safety, availability, and cost-effectiveness of methylphenidate compared with other stimulant (first-line) and non-stimulant (second-line) medications.
    [Show full text]
  • The Stimulants and Hallucinogens Under Consideration: a Brief Overview of Their Chemistry and Pharmacology
    Drug and Alcohol Dependence, 17 (1986) 107-118 107 Elsevier Scientific Publishers Ireland Ltd. THE STIMULANTS AND HALLUCINOGENS UNDER CONSIDERATION: A BRIEF OVERVIEW OF THEIR CHEMISTRY AND PHARMACOLOGY LOUIS S. HARRIS Dcparlmcnl of Pharmacology, Medical College of Virginia, Virginia Commonwealth Unwersity, Richmond, VA 23298 (U.S.A.) SUMMARY The substances under review are a heterogenous set of compounds from a pharmacological point of view, though many have a common phenylethyl- amine structure. Variations in structure lead to marked changes in potency and characteristic action. The introductory material presented here is meant to provide a set of chemical and pharmacological highlights of the 28 substances under con- sideration. The most commonly used names or INN names, Chemical Abstract (CA) names and numbers, and elemental formulae are provided in the accompanying figures. This provides both some basic information on the substances and a starting point for the more detailed information that follows in the individual papers by contributors to the symposium. Key words: Stimulants, their chemistry and pharmacology - Hallucinogens, their chemistry and pharmacology INTRODUCTION Cathine (Fig. 1) is one of the active principles of khat (Catha edulis). The structure has two asymmetric centers and exists as two geometric isomers, each of which has been resolved into its optical isomers. In the plant it exists as d-nor-pseudoephedrine. It is a typical sympathomimetic amine with a strong component of amphetamine-like activity. The racemic mixture is known generically in this country and others as phenylpropanolamine (dl- norephedrine). It is widely available as an over-the-counter (OTC) anti- appetite agent and nasal decongestant.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Oregon Dur Board Newsletter a N E Vidence B Ased D Rug T Herapy R Esource  Copyright 2002 Oregon State University
    OREGON DUR BOARD NEWSLETTER A N E VIDENCE B ASED D RUG T HERAPY R ESOURCE COPYRIGHT 2002 OREGON STATE UNIVERSITY. ALL RIGHTS RESERVED Volume 4, Issue 2 Also available on the web and via e-mail list-serve at April 2002 http://pharmacy.orst.edu/drug_policy/drug_policy.html A Review of Stimulant Medications By Ann Hamer, Pharm. D., OSU College of Pharmacy Attention deficit hyperactivity disorder (ADHD) is a psychiatric disorder four hours (5,6). Measures of efficacy included behavior frequency, characterized by inattention, hyperactivity, or impulsivity that is more completion and accuracy of academic problems, independent frequent or severe than is appropriate for the patient’s developmental observations, as well as teacher and counselor ratings. The extended level(1). It is estimated that 3 to 7 % of children have ADHD making it one release property of Concerta is based on its OROS delivery system (an of the most common psychiatric disorders of childhood and osmotically active trilayer core surrounded by a semipermeable membrane adolescence(2). with an immediate-release drug overcoat)(7). PHARMACOTHERAPY Patients new to methylphenidate should start Concerta at a dose of 18mg Stimulants are considered first-line agents for the treatment of children once daily. The dose may be adjusted based on the patient’s response in (greater than six years of age) with ADHD and are the only agents increments of 18mg per week to a maximum recommended dose of approved by the Food and Drug Administration (FDA) for this purpose(3). 54mg/day. The recommended dose conversion for patients currently Stimulant medications (including methylphenidate preparations, taking methylphenidate is summarized as follows: dextroamphetamine preparations, and pemoline) have CNS and RECOMMENDED CURRENT METHYLPHENIDATE DOSE respiratory stimulant properties and weak sympathomimetic activity.
    [Show full text]
  • Provider Notice
    Mental Health Provider Quick Reference ▪ For current information visit http://kentucky.fhsc.com/pharmacy/default.asp ▪ To access the complete Preferred Drug List, click on the "Providers" tab and select "Drug Information" ▪ Managed Access Program/Prior Authorization: 800-477-3071 ▪ Mental Health Provider Prior Authorization FAX line: 800-453-2273 Class All are covered first tier with PA which may be obtained electronically (or by fax) within appropriate dosage, duplicate therapy Atypical Antipsychotics and ICD9 requirements Class First Generation Antipsychotics All are covered first tier without restriction Class Anticonvulsants All generic products are covered first tier without restriction. Brand products are second tier. CNS Stimulants for Patients <= 18 years old DRUG COPAY TIER PA MAXIMUM QUANTITY COMMENTS REQUIRED AVAILABLE WITHOUT (CLINICAL OR PRIOR AUTHORIZATION PDL) ALONE COMBINED SHORT-ACTING CNS STIMULANTS Adderall N/A NO 90 Any Patient may receive a total of up to 90 Amphetamine salt combo combination of dosage units/30 days alone, or in short-acting combination with other short-acting Dexmethylphenidate CNS stimulants (Adderall, Amphetamine Salt Focalin Stimulants not Combo, Dexmethylphenidate, and Focalin), to exceed 90 independent of long-acting stimulants dosage units (Adderall XR, Concerta, Focalin XR, and Vyvanse) and Strattera quantities LONG-ACTING CNS STIMULANTS Adderall XR N/A NO 60 Any Patient may receive a total of up to 60 Concerta combination of dosage units/30 days alone, or in Focalin XR extended combination
    [Show full text]
  • Dexmethylphenidate
    MICROMEDEX® Healthcare Series : Document Page 1 of 31 Case 3:09-cv-00080-TMB Document 78-23 Filed 03/24/2010 Page 1 of 105 DRUGDEX® Evaluations DEXMETHYLPHENIDATE 0.0 Overview 1) Class a) This drug is a member of the following class(es): Amphetamine Related CNS Stimulant 2) Dosing Information a) Dexmethylphenidate Hydrochloride 1) Adult a) Attention deficit hyperactivity disorder 1) extended-release: methylphenidate-naive patients, initial 10 mg ORALLY daily in the morning; adjust dose weekly in 10 mg increments; MAX 20 mg/day 2) extended-release: patients currently using methylphenidate, one-half the total daily dose of racemic methylphenidate; patients currently using dexmethylphenidate immediate-release may be switched to the same daily dose of dexmethylphenidate extended-release; MAX 20 mg/day 2) Pediatric a) safety and efficacy not established in patients under 6 years of age 1) Attention deficit hyperactivity disorder a) immediate-release (ages 6 years and older): methylphenidate-naive patients, initial 2.5 mg ORALLY twice daily; adjust dose weekly in 2.5 to 5 mg increments; MAX 20 mg/day (10 mg twice a day) b) immediate-release (ages 6 years and older): patients currently using methylphenidate, one-half the dose of racemic methylphenidate; MAX 20 mg/day (10 mg twice a day) c) extended-release (ages 6 years and older): methylphenidate-naive patients, initial 5 mg ORALLY in the morning; adjust dose weekly in 5 mg increments; MAX 20 mg/day(Prod Info FOCALIN XR(R) extended-release oral capsules, 2008) d) extended-release (ages 6 years
    [Show full text]
  • Drug Abuse Urine Tests: False-Positive Results Joseph A
    University of the Pacific Scholarly Commons School of Pharmacy and Health Sciences Faculty Thomas J. Long School of Pharmacy and Health Articles Sciences 3-1-2005 Drug abuse urine tests: false-positive results Joseph A. Woelfel University of the Pacific, [email protected] Follow this and additional works at: https://scholarlycommons.pacific.edu/phs-facarticles Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Woelfel, J. A. (2005). Drug abuse urine tests: false-positive results. Pharmacist’s Letter & Prescriber’s Letter, 21(3), 1–5. https://scholarlycommons.pacific.edu/phs-facarticles/49 This Article is brought to you for free and open access by the Thomas J. Long School of Pharmacy and Health Sciences at Scholarly Commons. It has been accepted for inclusion in School of Pharmacy and Health Sciences Faculty Articles by an authorized administrator of Scholarly Commons. For more information, please contact [email protected]. ® Detail-Document #210314 ® −This Detail-Document accompanies the related article published in− PHARMACIST’S LETTER / PRESCRIBER’S LETTER March 2005 ~ Volume 21 ~ Number 210314 Drug Abuse Urine Tests: False-positive Results Lead author: Joseph A. Woelfel, Ph.D., FASCP, R.Ph., Assistant Editor Health care professionals are frequently asked questions about false-positive drug testing results. Testing is a common practice in work settings, rehabilitation programs, the military, and legal and judicial venues. Home testing is popular with the availability of test kits to alleviate parental or job-seeker concerns. Federally regulated workplace drug testing and most private sector workplace programs specify urine testing as their initial standard test. Other expanded tests may be required in some settings.
    [Show full text]
  • Controlled Drug Schedules, Violations & Penalties
    CONTROLLED DRUG SCHEDULES, VIOLATIONS & PENALTIES A REFERENCE FOR THE LAW ENFORCEMENT COMMUNITY April 2015 Prepared by the DEPARTMENT OF CONSUMER PROTECTION Drug Control Division TABLE OF CONTENTS SECTION I CONTROLLED DRUG SCHEDULES & VIOLATIONS An alphabetical listing of controlled drugs by their brand, generic and/or street name that includes each drug’s schedule and the violation(s) from the Connecticut General Statutes (CGS) that are associated with each drug’s sale and/or possession. SECTION II CONTROLLED DRUG VIOLATIONS & PENALTIES A numerical listing of controlled drug violations by their section number in the Connecticut General Statutes (CGS) and the penalty(ies) associated with each violation. SECTION III SUMMARY OF FEDERAL METHAMPHETAMINE STATUTES 2 S E C T I O N I CONTROLLED DRUG SCHEDULES & VIOLATIONS The ‘Schedules of Controlled Substances’ may be found in Sections 21a-243-7 through 21a-243-11, inclusive, of the Regulations of Connecticut State Agencies. www.ct.gov/dcp/lib/dcp/dcp_regulations/21a-243_designation_of_controlled_drugs.pdf 3 Drug State CS Drug Type AKA Sale or Quantity Person Drug- CGS Schedule Possession? Dependent or Not Violation APAP = Acetaminophen APAP = Acetaminophen Drug-Dependent ? ASA = Aspirin ASA = Aspirin “2C-C” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-D” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-E” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-H” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-I” Designer Drug - Stimulant
    [Show full text]
  • Introduced B.,Byhansen, 16
    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
    [Show full text]
  • Schedules of Controlled Substances (.Pdf)
    PURSUANT TO THE TEXAS CONTROLLED SUBSTANCES ACT, HEALTH AND SAFETY CODE, CHAPTER 481, THESE SCHEDULES SUPERCEDE PREVIOUS SCHEDULES AND CONTAIN THE MOST CURRENT VERSION OF THE SCHEDULES OF ALL CONTROLLED SUBSTANCES FROM THE PREVIOUS SCHEDULES AND MODIFICATIONS. This annual publication of the Texas Schedules of Controlled Substances was signed by John Hellerstedt, M.D., Commissioner of Health, and will take effect 21 days following publication of this notice in the Texas Register. Changes to the schedules are designated by an asterisk (*). Additional information can be obtained by contacting the Department of State Health Services, Drugs and Medical Devices Unit, P.O. Box 149347, Austin, Texas 78714-9347. The telephone number is (512) 834-6755 and the website address is http://www.dshs.texas.gov/dmd. SCHEDULES Nomenclature: Controlled substances listed in these schedules are included by whatever official, common, usual, chemical, or trade name they may be designated. SCHEDULE I Schedule I consists of: -Schedule I opiates The following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, if the existence of these isomers, esters, ethers, and salts are possible within the specific chemical designation: (1) Acetyl-α-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide); (2) Acetylmethadol; (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) (Other name:
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four-hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them, and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]